Sitagliptin: Difference between revisions
From Proteopedia
Jump to navigationJump to search
David Canner (talk | contribs) No edit summary |
David Canner (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
<applet load="" size="480" color="" frame="true" spin="on" Scene ="Sitagliptin/Sitagliptin/1" align="right" caption="Sitagliptin, better known as Januvia, ([[1x70]])"/> | <applet load="" size="480" color="" frame="true" spin="on" Scene ="Sitagliptin/Sitagliptin/1" align="right" caption="Sitagliptin, better known as Januvia, ([[1x70]])"/> | ||
===Better Known as: Januvia=== | ===Better Known as: Januvia=== | ||
* Marketed By: | * Marketed By: Merck & Co. | ||
* Major Indication: | * Major Indication: [[Hyperglycemia & Type II Diabetes]] | ||
* Drug Class: | * Drug Class: Dipeptidyl Peptidase-4 (DPP-4) Inhibitor | ||
* Date of FDA Approval (Patent Expiration): | * Date of FDA Approval (Patent Expiration): 2006 (2017) | ||
* 2009 Sales: | * 2009 Sales: $2.4 Billion | ||
* Importance: | * Importance: | ||
* See [[Pharmaceutical Drugs]] for more information about other drugs and diseases. | * See [[Pharmaceutical Drugs]] for more information about other drugs and diseases. | ||
Revision as of 10:48, 13 December 2010
|
Better Known as: Januvia
- Marketed By: Merck & Co.
- Major Indication: Hyperglycemia & Type II Diabetes
- Drug Class: Dipeptidyl Peptidase-4 (DPP-4) Inhibitor
- Date of FDA Approval (Patent Expiration): 2006 (2017)
- 2009 Sales: $2.4 Billion
- Importance:
- See Pharmaceutical Drugs for more information about other drugs and diseases.
Mechanism of Action
Pharmacokinetics
For Pharmacokinetic Data References, see: References |
|||||||||||||||||||||||||||||||||||||||||||||||||||||
References
